A detailed history of Baker Bros. Advisors LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 23,222,222 shares of SMMT stock, worth $464 Million. This represents 2.41% of its overall portfolio holdings.

Number of Shares
23,222,222
Holding current value
$464 Million
% of portfolio
2.41%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.39 - $10.92 $55.5 Million - $254 Million
23,222,222 New
23,222,222 $181 Million
Q3 2023

Nov 14, 2023

SELL
$1.54 - $2.42 $4.87 Million - $7.66 Million
-3,164,232 Reduced 50.19%
3,140,473 $5.87 Million
Q1 2023

May 15, 2023

BUY
$1.38 - $5.41 $5.94 Million - $23.3 Million
4,304,705 Added 215.24%
6,304,705 $11 Million
Q4 2022

Feb 14, 2023

BUY
$0.68 - $5.31 $1.36 Million - $10.6 Million
2,000,000 New
2,000,000 $8.5 Million

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $4.02B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.